REVIEW ARTICLE

Development of a Targeted Drug Delivery System for Colon-Specific Release: A Comprehensive Review

C. P. Sreekanth Reddy[1], G. Dharmamoorthy[2]

[1]Department of Pharmaceutical Sciences, MB School of Pharmaceutical Sciences, Mohan Babu University Tirupathi, Andhra Pradesh, India, [2]Department of Pharmaceutical Analysis, MB School of Pharmaceutical Sciences, Mohan Babu University, Tirupathi, Andhra Pradesh, India

Abstract

Colon-specific drug delivery systems have gained considerable attention due to their ability to deliver drugs selectively to the colon for both local and systemic therapeutic applications. These systems are particularly useful in the treatment of diseases such as ulcerative colitis, Crohn's disease, colorectal cancer, and irritable bowel syndrome. The colon offers a unique physiological environment, including near-neutral pH, reduced enzymatic activity, and prolonged transit time, which can be exploited for targeted drug delivery. However, several physiological barriers, such as variable pH, enzymatic degradation, and gastrointestinal transit, pose challenges in achieving precise drug release. This review discusses the anatomy and physiology of the colon, various approaches to colon targeting, formulation strategies, polymers used, recent advancements including nanoparticle-based systems, evaluation techniques, and future perspectives.

Key words: Colon targeting, colon-specific drug delivery systems, colorectal cancer, controlled drug release, nanoparticle-based drug delivery, polymers, ulcerative colitis

INTRODUCTION

Targeted drug delivery systems aim to deliver therapeutic agents specifically to the site of action, thereby enhancing efficacy and minimizing systemic side effects. Colon-targeted drug delivery is particularly beneficial for treating local diseases of the colon and for systemic delivery of drugs that are poorly absorbed in the upper gastrointestinal tract (GIT).[1,2]

Oral colon-targeted systems protect drugs from degradation in the stomach and small intestine and enable controlled or site-specific release in the colon. These systems are increasingly important for delivering proteins, peptides, and anticancer drugs.[3,4]

ANATOMY AND PHYSIOLOGY OF THE COLON

The colon is the terminal part of the GIT and plays a crucial role in water absorption and fecal storage. Key features influencing drug delivery include.[5,6]

- pH range: ~6.4–7.5
- Transit time: 20–30 h
- Microflora: Rich in bacteria producing enzymes such as β-glucosidase, pectinase, and azoreductase
- Low enzymatic activity: Favorable for peptide drugs.

The presence of microbial enzymes enables the degradation of specific polymers, making them ideal triggers for colon-targeted systems.

RATIONALE FOR COLON-SPECIFIC DRUG DELIVERY

Colon targeting offers several advantages:

- Site-specific treatment of colonic diseases
- Reduced systemic side effects

Address for correspondence:
Dr. G. Dharmamoorthy, Department of Pharmaceutical Analysis, MB School of Pharmaceutical Sciences, Mohan Babu University, Tirupati - 517 102, Andhra Pradesh, India. E-mail: dharmamoorthy111@gmail.com

Received: 23-05-2026
Revised: 22-06-2026
Accepted: 29-06-2026

- Improved bioavailability of unstable drugs
- Enhanced patient compliance.

Diseases targeted include:
- Ulcerative colitis
- Crohn's disease
- Colorectal cancer
- Amoebiasis.

CHALLENGES IN COLON TARGETING

Despite advantages, several challenges exist.[7-9]
- Variable gastrointestinal (GI) pH
- Enzymatic degradation in upper GIT
- Gastric emptying variability
- Premature drug release.

Successful systems must remain intact in the stomach and small intestine and release drugs only in the colon.

APPROACHES TO COLON-SPECIFIC DRUG DELIVERY

pH-dependent systems

These systems use polymers that dissolve at higher pH levels of the colon.[10]

Common polymers:
- Eudragit® S100, L100
- Cellulose acetate phthalate
- Hydroxypropyl methylcellulose phthalate.

These polymers resist gastric pH but dissolve in colonic pH, enabling drug release.

Time-dependent systems

These rely on GI transit time. Drug release occurs after a predetermined lag time corresponding to arrival in the colon.[11,12]

Limitation: High variability in transit time.

Microbially triggered systems

These systems utilize biodegradable polymers degraded by colonic bacteria.

Examples:
- Guar gum
- Pectin
- Chitosan
- Dextran.

These polymers remain intact in the upper GIT and are degraded in the colon by bacterial enzymes.

Prodrug approach

Drugs are chemically modified into inactive forms that are activated in the colon.[13]

Example:
- Sulfasalazine → metabolized by colonic bacteria.

Pressure-controlled systems

These systems exploit increased luminal pressure in the colon to trigger drug release.

Multiparticulate systems

Includes pellets, microspheres, and nanoparticles.

Advantages:
- Uniform distribution
- Reduced dose dumping
- Improved targeting.

POLYMERS USED IN COLON TARGETING[14,15]

Natural polymers

- Guar gum
- Pectin
- Chitosan
- Dextran.

These are biodegradable, safe, and cost-effective.

Synthetic polymers

- Eudragit polymers
- Polyacrylates
- Cellulose derivatives.

These provide controlled and reproducible drug release.

Smart polymers

Respond to environmental triggers such as:
- pH
- Enzymes
- Temperature.

These polymers improve precision in drug delivery.

NOVEL DRUG DELIVERY SYSTEMS

Nanoparticles

Nanocarriers enhance targeting efficiency and reduce toxicity.

Recent studies show nanoparticle systems can achieve sustained and colon-specific drug release with high encapsulation efficiency and controlled kinetics.[16]

Liposomes and dendrimers

- Improve drug solubility
- Enable targeted delivery.

Mesoporous silica nanoparticles

Offer:
- High drug loading
- Controlled release
- Targeted delivery in colorectal cancer.

Hydrogel-based systems

Hydrogels swell in response to pH changes and release drugs selectively.

EVALUATION OF COLON TARGETED DRUG DELIVERY SYSTEMS[17,18]

In vitro studies

- Dissolution testing in simulated GI fluids
- Enzyme-triggered release studies.

In vivo studies

- Animal models
- Gamma scintigraphy
- Pharmacokinetic studies.

Stability studies

- ICH guidelines
- Long-term and accelerated stability.

APPLICATIONS

Local therapy

- Inflammatory bowel disease
- Colon cancer.

Systemic therapy

- Protein and peptide drugs
- Vaccines.

RECENT ADVANCES AND RESEARCH TRENDS[19,20]

Recent developments focus on:
- Nanotechnology-based delivery
- Multi-trigger systems (pH + microbial)
- AI-assisted formulation design
- Personalized medicine.

Nanoparticle systems and hybrid formulations are emerging as promising strategies to overcome traditional limitations.

FUTURE PERSPECTIVES

Future research should focus on:
- Clinical translation of nanoparticle systems
- Improved targeting accuracy
- Cost-effective formulations
- Regulatory approval pathways.

Integration of biotechnology and nanotechnology is expected to revolutionize colon-targeted drug delivery.

CONCLUSION

Colon-specific drug delivery systems represent a promising strategy for targeted therapy of colonic diseases and systemic delivery of sensitive drugs. Advances in polymer science, nanotechnology, and formulation strategies have significantly improved the efficiency of these systems. However, challenges such as variability in GI conditions and large-scale manufacturing remain. Continued research and innovation are essential to translate these systems into clinically viable therapies.

REFERENCES

1. Rajpurohit H, Sharma P, Sharma S, Bhandari A. Polymers for colon targeted drug delivery. Indian J Pharm Sci 2010;72:689-96.
2. Philip AK, Philip B. Colon targeted drug delivery systems: A review. J Pharm Sci 2010;13:235-46.
3. Vemula SK, Veerareddy PR. Colon-specific drug delivery systems: A review. Int J Pharm Sci Res 2012;3:687-98.
4. Amidon S, Brown JE, Dave VS. Colon-targeted oral drug delivery systems: Design trends and approaches. AAPS Pharm Sci Tech 2015;16:731-41.

5. Ibekwe VC, Fadda HM, McConnell EL, Khela MK, Evans DF, Basit AW. Interplay between intestinal pH, transit time and feed status on the *in vivo* performance of pH responsive ileo-colonic release systems. Pharm Res 2008;25:1828-35.
6. Ashford M, Fell JT, Attwood D, Sharma H, Woodhead PJ. Studies on pH-dependent polymers for colon-targeted drug delivery. J Control Release 1993;26:213-20.
7. Sinha VR, Kumria R. Polysaccharides in colon-specific drug delivery. Int J Pharm 2001;224:19-38.
8. Sinha VR, Kumria R. Microbially triggered drug delivery to the colon. Eur J Pharm Sci 2003;18:3-18.
9. Yang L, Chu JS, Fix JA. Colon-specific drug delivery: New approaches and *in vitro/in vivo* evaluation. Int J Pharm 2002;235:1-15.
10. Tozaki H, Komoike J, Tada C, Maruyama T, Terabe A, Suzuki T, *et al*. Chitosan capsules for colon-specific drug delivery: Improvement of insulin absorption from the rat colon. J Pharm Sci 1997;86:1016-21.
11. McConnell EL, Short MD, Basit AW. An *in vivo* comparison of pH-sensitive coatings for colonic targeting. J Drug Target 2008;16:706-14.
12. Hua S. Advances in nanoparticulate drug delivery approaches for colorectal cancer. Front Pharmacol 2014;5:138.
13. Zhang Y, Chan HF, Leong KW. Advanced materials and processing for drug delivery: The past and the future. Adv Drug Deliv Rev 2013;65:104-20.
14. Maroni A, Del Curto MD, Zema L, Foppoli A, Gazzaniga A. Film coatings for oral colon delivery. Int J Pharm 2013;457:372-94.
15. Jung YS, Kim SK, Kim JH. Colon-targeted delivery using biodegradable polymers. J Control Release 2001;77:65-74.
16. Patel A, Patel M, Yang X, Mitra AK. Recent advances in protein and peptide drug delivery. Drug Discov Today 2014;19:754-62.
17. Vilar G, Tulla-Puche J, Albericio F. Polymers and drug delivery systems. Curr Drug Deliv 2012;9:367-94.
18. Hua S. Targeting sites of inflammation: Colon drug delivery. J Control Release 2020;319:113-25.
19. Amidon GL, Lennernäs H, Shah VP, Crison JR. Biopharmaceutics classification system (BCS). Pharm Res 1995;12:413-20.
20. International Council for Harmonisation (ICH). ICH Q1A(R2): Stability Testing of New Drug Substances and Products. Geneva, Switzerland: International Council for Harmonisation; 2003.

Source of Support: Nil. **Conflicts of Interest:** None declared.